J05AJ01 • raltegravir • Antiinfectives for systemic use | Direct acting antivirals | Integrase inhibitors
Raltegravir is a medication used for the treatment of human immunodeficiency virus (HIV) infection. It is an integrase inhibitor that prevents the integration of viral DNA into the host cell genome, thereby reducing viral replication.
The medication is taken orally, usually in tablet form, and should be used in combination with other antiretroviral drugs as directed by your doctor. It is important to adhere to the treatment regimen to prevent the development of viral resistance.
Side effects may include nausea, fatigue, headache, or insomnia. In rare cases, severe adverse effects such as allergic reactions or liver function impairment may occur, requiring immediate medical attention.
Patients should inform their doctor about any other medications being used or pre-existing conditions, such as liver diseases, to ensure the safe use of raltegravir.
Substance: raltegravir
Date of last drug list: 01-12-2022
Commercial code: W52764002
Concentration: 400mg
Pharmaceutical form: tablets
Quantity: 180
Product type: original
Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).